June 2021—Biocept announced it will collaborate with Protean BioDiagnostics to research the ability of Biocept’s Target Selector molecular assay to determine EGFR status in non-small cell lung cancer patients.
Protean BioDiagnostics plans to validate the analytical performance of a laboratory-developed test based on Biocept’s EGFR assay test kit in accordance with the validation process requirements of the College of American Pathologists. The research will be conducted in an independent pathology laboratory setting.
Biocept’s research use only, CE-IVD-marked assay kit enables molecular laboratories to use its Target Selector platform to analyze formalin-fixed, paraffin-embedded tissue samples and circulating tumor DNA from biological fluids. Target Selector assays with Switch-Blocker technology provide results with a DNA input of as little as 4.6 ng, which may allow laboratories to eliminate macro-dissection of tumor blocks, potentially resulting in workflow improvements and cost savings.
The quantitative assays can be used in combination with a variety of platforms including qPCR, Sanger sequencing, microarrays, and mass spectrometry, in addition to next-generation sequencing.
Biocept, 888-332-7729
Protean BioDiagnostics, 754-242-9682